These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 33430071)

  • 1. Botulinum Toxin in Movement Disorders: An Update.
    Anandan C; Jankovic J
    Toxins (Basel); 2021 Jan; 13(1):. PubMed ID: 33430071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on new and unique uses of botulinum toxin in movement disorders.
    Jankovic J
    Toxicon; 2018 Jun; 147():84-88. PubMed ID: 28888928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum Toxin Therapy for Oromandibular Dystonia and Other Movement Disorders in the Stomatognathic System.
    Yoshida K
    Toxins (Basel); 2022 Apr; 14(4):. PubMed ID: 35448891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum toxin: State of the art.
    Jankovic J
    Mov Disord; 2017 Aug; 32(8):1131-1138. PubMed ID: 28639368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxin in movement disorders.
    Papapetropoulos S; Singer C
    Semin Neurol; 2007 Apr; 27(2):183-94. PubMed ID: 17390263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum Toxin Therapy for Parkinson's Disease.
    Wagle Shukla A; Malaty IA
    Semin Neurol; 2017 Apr; 37(2):193-204. PubMed ID: 28511260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum Toxin for the Treatment of Tremor and Tics.
    Lotia M; Jankovic J
    Semin Neurol; 2016 Feb; 36(1):54-63. PubMed ID: 26866497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.
    Hallett M; Albanese A; Dressler D; Segal KR; Simpson DM; Truong D; Jankovic J
    Toxicon; 2013 Jun; 67():94-114. PubMed ID: 23380701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case studies in movement disorders.
    Evidente VG; Caviness JN; Adler CH
    Semin Neurol; 2003 Sep; 23(3):277-84. PubMed ID: 14722823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on the neurologic applications of botulinum toxins.
    Evidente VG; Adler CH
    Curr Neurol Neurosci Rep; 2010 Sep; 10(5):338-44. PubMed ID: 20567945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum toxin treatment in parkinsonism.
    Anandan C; Jankovic J
    J Neurol Sci; 2024 Jan; 456():122810. PubMed ID: 38056063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin in movement disorders.
    Tater P; Pandey S
    Neurol India; 2018; 66(Supplement):S79-S89. PubMed ID: 29503330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease-oriented approach to botulinum toxin use.
    Jankovic J
    Toxicon; 2009 Oct; 54(5):614-23. PubMed ID: 19073203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin for the treatment of movement disorders.
    Thenganatt MA; Fahn S
    Curr Neurol Neurosci Rep; 2012 Aug; 12(4):399-409. PubMed ID: 22661378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B.
    Oshima M; Deitiker PR; Jankovic J; Duane DD; Aoki KR; Atassi MZ
    J Neuroimmunol; 2011 Dec; 240-241():121-8. PubMed ID: 22079193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An update on the use of botulinum toxin therapy in Parkinson's disease.
    Mills R; Bahroo L; Pagan F
    Curr Neurol Neurosci Rep; 2015 Jan; 15(1):511. PubMed ID: 25407133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Botulinum Toxin in Orofacial Clinical Practice.
    Serrera-Figallo MA; Ruiz-de-León-Hernández G; Torres-Lagares D; Castro-Araya A; Torres-Ferrerosa O; Hernández-Pacheco E; Gutierrez-Perez JL
    Toxins (Basel); 2020 Feb; 12(2):. PubMed ID: 32053883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Injectable neuromuscular blockade in the treatment of spasticity and movement disorders.
    Tilton AH
    J Child Neurol; 2003 Sep; 18 Suppl 1():S50-66. PubMed ID: 13677571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin: clinical use.
    Truong DD; Jost WH
    Parkinsonism Relat Disord; 2006 Sep; 12(6):331-55. PubMed ID: 16870487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum toxin in movement disorders.
    Jankovic J
    Curr Opin Neurol; 1994 Aug; 7(4):358-66. PubMed ID: 7952246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.